A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

NCT05171777 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Atezolizumab

Sponsor

Hoffmann-La Roche